Lipocalin 2 mediates appetite suppression during pancreatic cancer cachexia
Lipocalin 2 (LCN2) has been recently identified as an endogenous regulator of appetite. Here, using pancreatic cancer as a model of cachexia, the authors demonstrate that LCN2 is a critical mediator of cancer-associated anorexia and may be therapeutically targeted to improve patient outcomes.
Guardado en:
Autores principales: | Brennan Olson, Xinxia Zhu, Mason A. Norgard, Peter R. Levasseur, John T. Butler, Abigail Buenafe, Kevin G. Burfeind, Katherine A. Michaelis, Katherine R. Pelz, Heike Mendez, Jared Edwards, Stephanie M. Krasnow, Aaron J. Grossberg, Daniel L. Marks |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/abf8c7f4da7a45d4af0d1631fd583659 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Publisher Correction: The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer
por: Katherine A. Michaelis, et al.
Publicado: (2019) -
The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer
por: Katherine A. Michaelis, et al.
Publicado: (2019) - Appetite
-
Disposal of iron by a mutant form of lipocalin 2
por: Jonathan Barasch, et al.
Publicado: (2016) -
Activation of the Complement System in Patients with Cancer Cachexia
por: Min Deng, et al.
Publicado: (2021)